Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia

被引:3
作者
Jeyaraman, Preethi [1 ]
Naithani, Rahul [1 ]
机构
[1] Max Super Specialty Hosp, Div Hematol & Bone Marrow Transplant, New Delhi, India
关键词
Imatinib cessation; pediatric CML; tyrosine kinase inhibitors; MOLECULAR RESPONSE;
D O I
10.1097/MPH.0000000000001624
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic myeloid leukemia (CML) has different disease biology with a more aggressive clinical course in children. Achieving treatment-free remission is the ideal goal for the pediatric CML population to avoid long-term toxicities of tyrosine kinase inhibitors. Here, we present our experience of stopping Imatinib in a pediatric patient of CML who had excessive weight gain with Imatinib. He is currently maintaining treatment-free remission for 15 months after stopping therapy at the time of last follow-up. The patient also had normalization of body mass index with the stopping of Imatinib.
引用
收藏
页码:E64 / E65
页数:2
相关论文
共 10 条
[1]   Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy [J].
Aduwa, Elvis ;
Szydlo, Richard ;
Marin, David ;
Foroni, Letizia ;
Reid, Alistair ;
Goldman, John ;
Apperley, Jane F. ;
Milojkovic, Dragana .
BLOOD, 2012, 120 (25) :5087-5088
[2]   Imatinib has adverse effect on growth in children with chronic myeloid leukemia [J].
Bansal, Deepak ;
Shava, Upender ;
Varma, Neelam ;
Trehan, Amita ;
Marwaha, R. K. .
PEDIATRIC BLOOD & CANCER, 2012, 59 (03) :481-484
[3]   Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients [J].
Carlos Hernandez-Boluda, Juan ;
Pereira, Arturo ;
Pastor-Galan, Irene ;
Alvarez-Larran, Alberto ;
Savchuk, Alisa ;
Manuel Puerta, Jose ;
Maria Sanchez-Pina, Jose ;
Collado, Rosa ;
Diaz-Gonzalez, Alvaro ;
Angona, Anna ;
Sagues, Miguel ;
Garcia-Gutierrez, Valentin ;
Boque, Concepcion ;
Osorio, Santiago ;
Vallansot, Rolando ;
Palomera, Luis ;
Mendizabal, Arantxa ;
Felipe Casado, Luis ;
Perez-Encinas, Manuel ;
Perez-Lopez, Raul ;
Ferrer-Marin, Francisca ;
Sanchez-Guijo, Fermin ;
Garcia, Carmen ;
de las Heras, Natalia ;
Luis Lopez-Lorenzo, Jose ;
Cervantes, Francisco ;
Luis Steegmann, Juan .
BLOOD CANCER JOURNAL, 2018, 8
[4]   De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial [J].
Clark, Richard E. ;
Polydoros, Fotios ;
Apperley, Jane F. ;
Milojkovic, Dragana ;
Rothwell, Katherine ;
Pocock, Christopher ;
Byrne, Jennifer ;
de lavallade, Hugues ;
Osborne, Wendy ;
Robinson, Lisa ;
O'Brien, Stephen G. ;
Read, Lucy ;
Foroni, Letizia ;
Copland, Mhairi .
LANCET HAEMATOLOGY, 2019, 6 (07) :E375-E383
[5]   De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial [J].
Clark, Richard E. ;
Polydoros, Fotios ;
Apperley, Jane F. ;
Milojkovic, Dragana ;
Pocock, Christopher ;
Smith, Graeme ;
Byrne, Jenny L. ;
de lavallade, Hugues ;
O'Brien, Stephen G. ;
Coffey, Tony ;
Foroni, Letizia ;
Copland, Mhairi .
LANCET HAEMATOLOGY, 2017, 4 (07) :E310-E316
[6]   Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study [J].
de Bruijn, Clara M. A. ;
Millot, Frederic ;
Suttorp, Meinolf ;
Borisevich, Marina ;
Brons, Paul ;
Lausen, Birgitte ;
de Bont, Eveline S. J. M. .
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (04) :718-724
[7]   Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia [J].
Etienne, Gabriel ;
Guilhot, Joelle ;
Rea, Delphine ;
Rigal-Huguet, Francoise ;
Nicolini, Franck ;
Charbonnier, Aude ;
Guerci-Bresler, Agnes ;
Legros, Laurence ;
Varet, Bruno ;
Gardembas, Martine ;
Dubruille, Viviane ;
Tulliez, Michel ;
Noel, Marie-Pierre ;
Ianotto, Jean-Christophe ;
Villemagne, Bruno ;
Carre, Martin ;
Guilhot, Francois ;
Rousselot, Philippe ;
Mahon, Francois-Xavier .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (03) :298-+
[8]   Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study [J].
Lee, Sung-Eun ;
Choi, Soo Young ;
Song, Hye-Young ;
Kim, Soo-Hyun ;
Choi, Mi-Yeon ;
Park, Joon Seong ;
Kim, Hyeoung-Joon ;
Kim, Sung-Hyun ;
Zang, Dae Young ;
Oh, Sukjoong ;
Kim, Hawk ;
Do, Young Rok ;
Kwak, Jae-Yong ;
Kim, Jeong-A ;
Kim, Dae-Young ;
Mun, Yeung-Chul ;
Lee, Won Sik ;
Chang, Myung Hee ;
Park, Jinny ;
Kwon, Ji Hyun ;
Kim, Dong-Wook .
HAEMATOLOGICA, 2016, 101 (06) :717-723
[9]   Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study [J].
Millot, Frederic ;
Guilhot, Joelle ;
Baruchel, Andre ;
Petit, Arnaud ;
Bertrand, Yves ;
Mazingue, Francoise ;
Lutz, Patrick ;
Verite, Cecile ;
Berthou, Christian ;
Galambrun, Claire ;
Sirvent, Nicolas ;
Yakouben, Karima ;
Schmitt, Claudine ;
Gandemer, Virginie ;
Reguerre, Yves ;
Couillault, Gerard ;
Mechinaud, Francoise ;
Cayuela, Jean-Michel .
BLOOD, 2014, 124 (15) :2408-2410
[10]   Imatinib Cessation in Children and Adolescents With Chronic Myeloid Leukemia in Chronic Phase [J].
Millot, Frederic ;
Claviez, Alexander ;
Leverger, Guy ;
Corbaciglu, Selim ;
Groll, Andreas H. ;
Suttorp, Meinolf .
PEDIATRIC BLOOD & CANCER, 2014, 61 (02) :355-357